The German biotech group BioNTech is navigating a period of rare structural flux, with two parallel corporate dramas unfolding within weeks of each other. At the heart of the uncertainty is a leadership vacuum created by the impending departure of founders Ugur Sahin and Özlem Türeci, who will step down as CEO and chief medical officer at the end of 2026. Adding to the complexity, the company must finalise a binding agreement on the planned spinoff of its mRNA platform by June 30 — a deadline that has also rekindled takeover speculation among big pharma.
The shares, which recently changed hands at €80.50, have struggled to regain momentum since the departure announcement triggered a decline of over 20% in a single session. The stock now sits roughly 24% below the highs it touched last year, and the 50-day moving average of €80.66 acts as a near-term ceiling. With a 30-day annualised volatility of 28.34%, the equity is primed for sharp moves on any news concerning either the succession search or the corporate restructuring.
Succession Search and the Spinoff Clock
The supervisory board has launched a hunt for a new CEO, with a target to have a binding agreement on the spinoff concluded by the end of June. Under the plan, Sahin and Türeci would lead the mRNA unit as a standalone entity, freeing the parent company to focus entirely on commercialising its oncology assets. Market observers view the spinoff as a potential catalyst for a takeover, because any acquisition would logically need to occur before the split — after which the target would be significantly smaller.
Pfizer and Bristol Myers Squibb, both existing partners of BioNTech, have been named as plausible suitors, though neither has commented publicly. The patent cliff facing many large pharma houses makes BioNTech’s advanced mRNA platform and deep pipeline an attractive bolt-on, especially given the €16.8 billion in cash and securities the Mainz-based company holds.
ASCO Data Bolster the Clinical Case
At the ASCO annual meeting in late May, BioNTech presented encouraging data from its bispecific immune modulator Pumitamig (BNT327), developed jointly with Bristol Myers Squibb. In a Phase 2/3 study (ROSETTA Lung-02), the drug achieved a confirmed objective response rate of 57.1% in patients with non-squamous non-small cell lung cancer and 68.4% in the squamous subtype, both in combination with chemotherapy. The anti-tumour activity was described as consistent and positions Pumitamig as a potential first-line therapy for lung cancer.
Should investors sell immediately? Or is it worth buying BioNTech?
Separately, the company’s Gotistobart candidate demonstrated durable activity in heavily pre-treated ovarian cancer patients. These results, while early, reinforce the breadth of BioNTech’s oncology pipeline, which now includes 15 late-stage trials after the initiation of six additional Phase 3 studies this year.
Financial Strains Beneath the Cash Pile
Despite the sizeable cash buffer, BioNTech’s operating model is under pressure. Full-year 2026 revenue is forecast at up to €2.3 billion, while adjusted research spending could reach €2.5 billion. The net loss for the first quarter already widened to roughly €532 million, and management has flagged that no oncology product revenue is expected this year. The company is structurally spending more than it earns, gradually eroding the financial cushion.
To counter the burn, BioNTech aims to achieve €500 million in annual cost savings by 2029, with the freed-up funds redirected into the oncology pipeline. Analysts see a potential upside of around 32% from the current share price, but that target hinges on both resolving the leadership question and delivering positive late-stage data.
What Comes First: Clarity at the Top or Clinical Validation?
The market is watching two key dates: the June 30 business briefing and the full second-quarter results due in August. If the supervisory board presents a credible new CEO before that point, the stock could re-rate independent of any pipeline updates. The real prize would then be the subsequent data readouts for Gotistobart and the mRNA therapy BNT113 in head and neck cancer, both expected in the second half of the year.
Yet the order of events matters. A drawn-out succession process that extends into late 2026, combined with disappointing trial results, could trigger further downside. For now, the shares remain in a holding pattern — caught between a rich pipeline, a thinning cash pile, and a corporate governance saga that has yet to reach its denouement.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from June 29 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 29.
BioNTech: Buy or sell? Read more here...
